Both are leading GLP-1-based weight-loss treatments, but they don't work in exactly the same way. Here's a clear, balanced comparison of how they differ, and what that means for you.
Semaglutide acts on a single hormone pathway (GLP-1). Tirzepatide acts on two pathways at once (GLP-1 and GIP), which is why it's often described as a "dual-action" treatment. Both reduce appetite and support weight loss; tirzepatide is newer and works through an additional mechanism.
Key point: Neither is universally "better." Which is more appropriate depends on your health profile, history, and how your body responds, something only a licensed physician can determine.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut naturally releases after eating. By amplifying that signal, it reduces appetite, slows digestion, and helps you feel full sooner and for longer. It's the active ingredient in several well-known brand-name medications and is also available in compounded form through many telehealth programs.
Tirzepatide is a dual-action treatment. In addition to acting on the GLP-1 receptor like semaglutide, it also acts on the GIP (glucose-dependent insulinotropic polypeptide) receptor. This second pathway is thought to contribute to its effects on appetite and metabolism. Because it engages two receptors rather than one, some people respond differently to it than to semaglutide.
Both medications are typically delivered as a once-weekly injection, both are titrated (gradually increased) under medical supervision, and both can cause similar early side effects, most commonly mild gastrointestinal symptoms that tend to ease over time.
This is genuinely a medical decision, not a marketing one. A licensed physician weighs factors such as your medical history, other medications, how you tolerate treatment, and your goals. Some programs offer both options and adjust based on how you respond. The most important thing is that a qualified provider reviews your situation before anything is prescribed.
Important: Don't choose a medication based on internet comparisons alone. Use this as background to have a more informed conversation with the provider who reviews your case.
The programs we match you to include a physician review that helps determine the right treatment for your situation. Our quiz finds your fit in 60 seconds.
Take the QuizClinical research on FDA-approved brand-name tirzepatide and semaglutide suggests tirzepatide can produce greater average weight loss for many people, but results vary by individual. In the SURMOUNT-5 head-to-head trial, participants on tirzepatide lost 20.2% of their body weight on average over 72 weeks, compared with 13.7% on semaglutide.[1] "More effective on average" is not the same as "better for you specifically", tolerability and your health profile matter just as much. A physician can advise based on your case.
The side-effect profiles are broadly similar, most commonly mild gastrointestinal symptoms (nausea, reduced appetite) in the early weeks as the dose is increased.[1] Your prescribing physician monitors this and adjusts accordingly.
Many telehealth programs offer both semaglutide and tirzepatide options, in brand-name or compounded forms. Availability and pricing differ by program, our cost guide explains what affects the price.
Answer six quick questions and we'll match you to a LegitScript-certified program whose physicians can help determine the right treatment for you.
Take the Quiz, 60 SecondsAbout these figures: The clinical trial results cited on this page reflect the safety and efficacy of the FDA-approved brand-name medications that were studied (such as Wegovy®, Zepbound® and Foundayo™), used alongside a reduced-calorie diet and physical activity under clinical-trial conditions. Compounded medications do not undergo FDA evaluation for safety or effectiveness and were not studied in these trials; their efficacy and safety profiles may differ from the brand-name medications studied. Individual results vary. This information is educational and is not medical advice.
Price changes, new program reviews, and plain-English GLP-1 updates, straight to your inbox. Independent, and never sponsored by the programs we review.
By joining, you agree to receive emails from GLP One Guide. Unsubscribe anytime. We never sell your email. See our Privacy Policy.